CLOs on the Move

Galera Therapeutics

www.galeratx.com

 
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.galeratx.com
  • 45 Liberty Boulevard Suite 230
    Malvern, PA USA 19355
  • Phone: 610.725.1500

Executives

Name Title Contact Details

Similar Companies

Paddock Laboratories Inc

Paddock Laboratories is a privately-held niche-based pharmaceutical company located in Minneapolis, Minnesota. Bruce Paddock, President, founded the business in 1977 with only three employees. Today, Paddock employs over 250 people in the areas of

Cardurion

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Founded by physician-scientist, Michael E. Mendelsohn, M.D., and built by a team of physician-scientists and industry leaders with extensive experience in cardiovascular disease, drug development and business development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs to target major unmet needs in cardiovascular medicine. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.

Ferndale Laboratories

Perhaps the most important decision in determining the destiny of Ferndale Laboratories, Inc. was made in the Fall of 1975. At that time, Ferndale Laboratories, Inc. embarked on a mission to grow from a local pharmaceutical manufacturer to a company with

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

UniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.